Asset Details
Do you wish to reserve the book?
Pazopanib eye drops: a randomised trial in neovascular age-related macular degeneration
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Pazopanib eye drops: a randomised trial in neovascular age-related macular degeneration
Do you wish to request the book?
Pazopanib eye drops: a randomised trial in neovascular age-related macular degeneration
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Pazopanib eye drops: a randomised trial in neovascular age-related macular degeneration
2014
Overview
Aims To evaluate pazopanib eye drops in patients with subfoveal choroidal neovascularisation secondary to age-related macular degeneration. Methods 70 patients with minimally classic or occult subfoveal choroidal neovascularisation were randomly assigned to 5 mg/mL TID, 2 mg/mL TID, and 5 mg/mL QD pazopanib eye drops for 28 days in a multicentre, double-masked trial with an optional safety extension for up to 5 additional months. The primary outcomes were central retinal thickness (CRT) and best-corrected visual acuity (BCVA) at Day 29. Results No significant decrease from baseline in CRT was observed overall; however, an exploratory analysis showed improvement in CRT (mean decrease of 89 μm) in patients with the CFH TT genotype who received 5 mg/mL TID (p=0.01, n=5). Mean increases in BCVA were observed in the 5 mg/mL TID overall (4.32 letters (p=0.002, n=26)) and in those that with CFH Y402H TT (6.96 letters (p=0.02, n=5)) and CT (4.09 letters (p=0.05, n=9)) genotypes. No safety signals that precluded continued investigation were detected. Conclusions 5 mg/mL pazopanib eye drops resulted in mean improvement in BCVA at Day 29 and improvements in vision. However, improvement in macular oedema for age-related macular degeneration was found only in the subset of subjects with the CFH Y402H TT genotype, warranting further investigation.
Publisher
BMJ Publishing Group LTD
Subject
/ Choroidal Neovascularization - complications
/ Choroidal Neovascularization - drug therapy
/ Choroidal Neovascularization - metabolism
/ Dose-Response Relationship, Drug
/ Female
/ Humans
/ Macular Degeneration - complications
/ Macular Degeneration - drug therapy
/ Macular Degeneration - metabolism
/ Male
/ Pyrimidines - administration & dosage
/ Pyrimidines - pharmacokinetics
/ Studies
/ Sulfonamides - administration & dosage
/ Sulfonamides - pharmacokinetics
